Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Vectibix (panitumumab by Year

Name: Amgen Vectibix (panitumumab by Year (AMGN)
Creator: Amgen

Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide product sales ($M) ($M)

Quarterly Annual

Amgen Vectibix (panitumumab: $1,175M in FY2025, up 12.4% from a year earlier. That is the highest of the 11 years on record here.

Latest, FY2025

1,175

Period ended Dec 31, 2025

Change on a year earlier

+12.4%

1,045 in FY2024

History

11 years

Since FY2015

Sources

Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide product sales ($M) ($M)	Year on year	Source
FY2025	Dec 31, 2025	1,175	+12.4%	Form 10-K (filed 2026-02-13) ↗
FY2024	Dec 31, 2024	1,045	+6.2%	Form 10-K (filed 2026-02-13) ↗
FY2023	Dec 31, 2023	984	+10.2%	Form 10-K (filed 2026-02-13) ↗
FY2022	Dec 31, 2022	893	+2.3%	Form 10-K (filed 2025-02-14) ↗
FY2021	Dec 31, 2021	873	+7.6%	Form 10-K (filed 2024-02-14) ↗
FY2020	Dec 31, 2020	811	+9.0%	Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
FY2019	Dec 31, 2019	744	+7.7%	Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗
FY2018	Dec 31, 2018	691	+7.6%	Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗
FY2017	Dec 31, 2017	642	+5.1%	Form 10-K (filed 2018-02-13) ↗
FY2016	Dec 31, 2016	611	+11.3%	Form 10-K (filed 2018-02-13) ↗
FY2015	Dec 31, 2015	549	–	Form 10-K (filed 2018-02-13) ↗

Breakdown

What makes up vectibix (panitumumab

Cite this data

StockData. (2026). Amgen Vectibix (panitumumab ($M), annual FY2015–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-vectibix-ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.